2024年以来,政策方面不断发力,支持内地龙头企业赴港上市。政策端的支持使得A股企业迎来赴港上市的窗口期,已有多家A股上市公司筹备搭建“A+H”双融资平台,仅2025年初至今,就已有30家公司披露了港股IPO招股书,包含7家A股公司。其中生物医药产业尤为积极,恒瑞医药(600276.SH,股价44.64元,市值2847.59亿元)、百利天恒(688506.SH,股价194.72元,市值780.83...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.